H eparin is widely used within the intensive care population, either as thromboprophylaxis, treatment for thrombotic disorders or to facilitate extracorporeal circuits. Heparininduced thrombocytopenia (HIT) is a serious drug-related complication. With the invention of newer anticoagulant agents, has the time come to seriously consider an alternative to heparin?
Pathophysiology of HIT
HIT can be classified into two main types. Type 1 is the result of a non-immune mediated process causing a reduction in the number of platelets. It usually occurs within two days of heparin exposure, and the degree of thrombocytopenia is usually not significant. There is no increased risk of thrombosis or bleeding and heparin can be safely continued. 1, 2 HIT type 2 is an immune-mediated response occurring after the administration of heparin. Antibodies (immunoglobulin IgG) are produced against complexes between the heparin molecule and platelet factor 4 (PF4). [3] [4] [5] The immune complex formed between the antibodies and PF4 subsequently binds to platelets, causing their activation. This process then releases further PF4 and greater platelet aggregation occurs. Thrombi can form in either or both the arterial and venous systems. The rest of this article will focus on HIT type 2 only.
The anti-PF4-heparin antibodies are present in patients with HIT but are also found in patients exposed to heparin who have no clinical manifestation of the disease. This makes diagnosing HIT difficult, as a positive antibody test does not mean the patient has the disease. 3, 6 It is also possible to have thrombus formation as a result of HIT without significant thrombocytopenia, particularly if platelets are increased in response to an acute phase process.
Diagnosis
HIT normally presents between days five and ten after exposure to heparin. However, it can occur on day one if heparin has been administered within the last 100 days. 1, 5, 6 The diagnosis of HIT should be considered in any patient who develops significant thrombocytopenia or a 30-50% reduction from baseline after five days of heparin, if no other obvious cause such as sepsis can be identified. Evidence of new thrombosis is concerning and the diagnosis of HIT should be considered if the patient is receiving heparin even if the platelet count remains within normal limits. 5, 6 A scoring system, the 4T score, has been developed ( Table  1 ). This should be applied to any patient when the diagnosis of HIT is considered. If the score is low, no further action is required. If it is moderate to high, these patients should stop receiving heparin immediately and start an alternative anticoagulant, as they are at high risk of thrombosis and heparin will provide no protection. [5] [6] [7] They should undergo antibody testing to confirm the diagnosis. As mentioned, this test detects antibodies against heparin-PF4 complexes and is an enzyme-linked immunosorbent assay (ELISA). The test has a high false positive rate because it detects all circulating antibodies that bind heparin-PF4 complexes. A more specific test is the serotonin release assay used in some centres but it is more difficult to perform. It detects the release of serotonin, which occurs when platelets are activated in the presence of heparin.
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Heparin is widely used in the intensive care environment usually for thromboprophylaxis but also to facilitate extra-corporeal circuits such as renal replacement and ECMO. Heparin-induced thrombocytopenia (HIT) is a rare but extremely serious disorder. It is associated with significant morbidity and mortality. The diagnosis is often challenging particularly as thrombocytopenia can be caused by a number of other common conditions seen in intensive care. Unfortunately routine screening for HIT antibodies is not helpful as it is possible to have these but have no manifestation of the disease process. If the diagnosis of HIT is not considered and the patient does in fact have the disease process they are at risk of thrombotic episodes. This article reviews the pathophysiology of HIT and the challenges with making the diagnosis. We explore the role of newer anticoagulants that may have a role such as direct thrombin inhibitors.
Incidence and epidemiology of HIT
HIT occurs in approximately 3-5% of patients receiving unfractionated heparin. 2, 8, 9 The incidence is considerably lower for low-molecular weight heparin where it is reported to be approximately 1%. 2 There are very few studies reporting the incidence of HIT in intensive care patients, but a review article by Selleng et al suggested that the incidence was less than 1% in this population. They conclude that most cases of thrombocytopenia are from other causes. 10 Females and surgical patients have a greater incidence in the intensive care environment. 2, 6 The actual incidence may be lower in surgical patients, as it has been suggested that HIT is over-diagnosed in this group. 11 The dose of heparin also appears to be important, as HIT is more common in patients receiving therapeutic doses. Those receiving heparin prophylaxis often form the antibodies but do not develop the disease. This places these patients at risk if they subsequently require treatment-dose heparin. 2 HIT is associated with significant morbidity (thrombi can result in amputations and ischaemic strokes) and mortality, with reports in the literature of mortality rates up to 22%. 12
Treatment of HIT
The initial management is to stop heparin, as this will provide no protection from clot formation and will increase the risk of further thrombosis. An alternative anticoagulant agent should be introduced. 5 Alternative agents to heparin can be divided into direct thrombin inhibitors, heparinoids, warfarin, Factor Xa inhibitors, and defibrinating agents.
Heparinoids work as indirect factor Xa inhibitors and also have some effect on thrombin. 5 They have long half-lives and are associated with a high risk of bleeding in overdose, and can react with heparin antibodies. The only available product is danaparoid. 2 Its use in intensive care may be limited by the risk of bleeding and long half-life, particularly in renal impairment.
Warfarin should be avoided in the initial management of HIT because it causes a hypercoagulopathic state due to the shorter half-life of proteins C and S compared to factors V, VII and IX. It may have a role in the long-term management of thrombosis from HIT. 2, 5 Factor Xa inhibitors can be either direct or indirect inhibitors. The direct Xa inhibitors currently licensed for use in the UK are apixaban and rivaroxaban. These are both oral preparations making them less suitable in the intensive care environment. Fondaparinux is an indirect factor Xa inhibitor. It works by binding to antithrombin III which causes the inhibition of factor Xa. Fondaparinux has successfully been used for the treatment of HIT, 5 however, it is not licensed for this use. There are also case reports of HIT occurring with fondaparinux, but the risk is thought to be extremely low. 13, 14 Defibrinating agents are not ideal due to a slow onset of action and bleeding risk. These agents will not be discussed any further but are mentioned here for completeness.
Direct thrombin inhibitors will be discussed in greater detail as these agents could be suitable alternatives and some have a licence for the treatment of HIT.
Direct thrombin inhibitors
Thrombin is an important factor in the clotting process. It converts fibrinogen into insoluble fibrin and also through positive feedback mechanisms, activates factors V, VIII, XI and platelets. This leads to propagation of the clotting cascade. 15 Direct thrombin inhibitors, as the name suggests, inhibit thrombin directly and need no other co-factors ( Table 2) . They can be classified as bivalent or univalent agents. Bivalent agents bind to the active enzyme site on the thrombin molecule and to the exosite 1 receptor. Examples of these are lepirudin, desirudin and bivalirudin. Lepirudin and desirudin bind irreversibly to thrombin whereas bivalirudin can be cleaved from the molecule and reactivate thrombin. 15 Lepirudin has been discontinued by its manufacturer for commercial reasons and will not be discussed further.
Desirudin is available in both subcutaneous and intravenous preparations. It has been compared to argatroban (a univalent direct thrombin inhibitor) in the PREVENT-HIT study. 16 This was a randomised open-label pilot study comparing argatroban (IV) and desirudin (SC) in patients with presumed or confirmed HIT. This study was a pilot study and not powered to show any clinical difference between the two groups. From the limited data available, desirudin appears to compare favourably with argatroban at considerably less cost 16 but is not generally available in the UK. Bivalirudin has also been compared with argatroban in a retrospective analysis for the treatment of HIT, which demonstrated that bivalirudin could be used as an alternative, with similar complication rates. It has also been used in the intensive care environment for the treatment of HIT, described in a small retrospective cohort study. 17 Bivalirudin has some advantages; it has a short half-life and unlike desirudin, binds reversibly with thrombin and only 20% is cleared by the kidneys. Neither desirudin nor bivalirudin have a licence for the treatment of HIT, whereas argatroban does.
Of the univalent agents, dabigatran is an oral medication and so of little interest in the ICU setting. Argatroban is administered parenterally so is more suitable. It has been used in HIT more than other univalent agents. 15 Argatroban is a small molecule that non-covalently, reversibly binds to the active thrombin site. This prevents the activation of a number of factors (V, VII, XIII) and it also prevents fibrin formation and platelet aggregation. It does not interact with heparin-induced antibodies. 18 Argatroban has been used with success in patients suffering from HIT and has been licensed for this population. 5, [19] [20] [21] Argatroban has a short half-life (40-50 minutes), rapid onset of action and hepatic metabolism, meaning it can be used safely in patients with renal impairment, giving it some advantages over other direct thrombin inhibitors. It provides adequate anticoagulation without excessive bleeding in intensive care patients. 20, 21 Saugel et al carried out a retrospective analysis of 12 patients with either HIT or suspected HIT. 22 They demonstrated that argatroban appeared to be a safe alternative with no bleeding complications or thromboembolic events. This was a small population and care must be taken in interpreting the findings. However, other studies have found similar results and support their conclusions. Lewis et al carried out a prospective study of argatroban for the treatment of HIT between 1996-98. 19 There were 418 patient in the argatroban group and 185 in the historical control arm. Their primary end-point was a composite of death, amputations and new thrombosis. They showed a significant reduction in the primary end-point for the argatroban group.
The future
Currently there are no prospective, randomised control studies comparing different alternative anticoagulants to heparin in intensive care patients. Argatroban has been successfully used as an anticoagulant agent for renal replacement therapy. 23 Alternative agents to heparin should also be considered in extracorporeal circuits as thrombosis is a serious complication and this would avoid the possibility of HIT. Further work needs to be undertaken to compare heparin with the newer anticoagulants. The direct thrombin inhibitors argatroban or bivalirudin would appear to have favourable pharmacokinetic properties making them ideal agents to compare directly with heparin.
Heparin currently has the advantage of cost and familiarity over most of the newer agents. However if HIT can be avoided, along with its associated mortality and morbidity then the extra cost may be offset. Further research is required comparing heparin with newer agents particularly where unfractionated heparin is used.
